Yield of testing for micronutrient deficiencies associated with pancreatic exocrine insufficiency in a clinical setting: An observational study

Table 1 Demographics of patients with suspected or proven benign pancreatic disease investigated with Faecal Elastase-1 including documented symptoms at time of investigation

	PEI (FEL-1 < 200 µg/g)	No PEI (FEL-1 > 200 µg/g)
	n = 41, mean ± SD or n (%)	n = 71, mean ± SD or n (%)
Age (yr)	58.2 (13.2)	57.4 (5)
Female	14 (34)	44 (61)
BMI (kg/m2)	26.1 (5.9)	29.9 (7.1)
Type 1 diabetes mellitus	9 (22.0)	11 (15.4)
Type 2 diabetes mellitus	13 (31.7)	26 (36.6)
Alcohol (unit/wk)	17.7 ± (22.9)	12.3 ± (10.5)
Smoking (pack yr)	22.3 ± (21.5)	21.6 ± (20.5)
Morphological changes of CP1	22/41 (53.7)	10/41 (24.3)
Clinical symptoms
Abdominal pain	21	38
Diarrhoea	9	19
Steatorrhoea	2	0
Bloating	5	11
Weight loss	4	3

¹All patients with PEI and 41 patients without PEI but suspected pancreatic disease underwent cross-sectional imaging.

PEI: Pancreatic exocrine insufficiency; FEL-1: Faecal elastase-1; CP: Chronic pancreatitis; BMI: Body mass index.